AstraZeneca & Daiichi Sankyo
AstraZeneca in Oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
For more information please visit astrazeneca.com.au.
Daiichi Sankyo
Daiichi Sankyo is a global pharmaceutical company on a mission to become a global top ten leader in oncology by 2030. This was driven by the discovery of our proprietary DXdantibody drug conjugate (ADC) technology, which is poised to redefine the treatment of cancer. In Australia, we are growing a team with a passion for innovation and compassion for patients. We are working with more than 40 sites on 10 trials evaluating our DXd ADCs, with additional studies planned. We are committed to developing new ideas and innovations in partnership with local researchers, clinicians, patients, patient advocates and government to enrich the lives of those impacted by cancer.
Upcoming AstraZeneca and Daiichi Sankyo Education
